RNN Rexahn Pharmaceuticals, Inc.

4.04
+0.09  (2%)
Previous Close 3.95
Open 3.95
Price To book 85.87
Market Cap 102.70M
Shares 25,422,000
Volume 272,186
Short Ratio 2.40
Av. Daily Volume 5,694,580

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2018.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a initial data due at ASCO June 4, 2017. Abstract 4544.
RX-3117
Advanced bladder cancer
Phase 2a initial data due towards the end of 2017.
Supinoxin
Triple negative breast cancer
Updated Phase 2a data presented at ASCO GI January 20, 2017. Final data due 2H 2017.
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2a second stage enrolment commenced February 2016. Noted May 4, 2017 an update due later this year.
Archexin
Renal cell carcinoma (RCC) - cancer